Charles River Laboratories has launched its cloud-based Apollo platform with the aim of easing access to a plethora of study data to support clients with safety assessments and toxicology studies.
With Apollo, clients can use self-service tools that allow them to view the status of studies, data insights and analysis, as well as study documents. The platform also features a self-service quoting tool that generates enhanced budget forecasting, the company said in a March 13 press release.
“The build and deployment of Apollo is an instrumental piece of Charles River’s overall digital journey,” Chief Information Officer Mark Mintz said in the release. “By delivering high impact technology that gives clients greater access to data, we are enabling data-driven decision-making that creates value for their businesses and reaching our goal of creating efficiencies in the drug development process.”
Just last month, Charles River announced it was partnering with Pioneering Medicines, a drug development initiative housed within Flagship Pioneering, to use the CRO's Logica platform to single out small molecules that could be used to create new drug candidates across a portfolio of targets. The two noted the goal of the collaboration is to develop novel therapies for conditions that have largely gone untreated.